Vascudyne Announces Successful First Human Use of TRUE Vascular Graft for Hemodialysis Access - Seite 2

a dedicated team of scientists who are committed to innovating solutions with
our TRUE Tissue technology for highly demanding medical applications. We are
planning additional clinical studies in the next 12 months and will be
submitting for market acceptance in the years ahead. We have several more
product designs in development and are pursuing ways to accelerate these other
programs into the clinical stage. We believe the right material with the correct
strategy will help millions of patients across the globe live better lives."

Vascudyne licensed its proprietary TRUE Tissue technology developed by Professor
Robert Tranquillo and his colleagues from the University of Minnesota in 2017.

The TRUE Vascular Graft is not available for commercial sale.

About Vascudyne

Headquartered in the heart of Medical Alley in Minnesota, Vascudyne is on a
mission to improve patient care with regenerative biomaterials that are inspired
by nature. Vascudyne, a privately held company founded in 2014, uses the
TRUE(TM) Tissue technology to develop TRUE to Nature(TM) biomaterials for soft
tissue repair and replacement. For more information, please visit
https://www.vascudyne.com/ .

About TRUE Tissue Technology

TRUE(TM) Tissue is developed from cells isolated from donor tissue and is 100%
biological. There are no synthetic materials or chemical fixation used, and
implanted tissues are completely cell-derived and acellular. The TRUE Tissue
technology can be readily shaped into tubes, sheets, and other geometries making
it suitable for many soft tissue applications, is mechanically comparable to
native tissues, and is a ready to use, off-the-shelf allograft.

Forward Looking Statements

This announcement contains forward-looking statements. Such statements may
include, without limitation, statements identified by words such as "projects,"
"may," "will," "could," "would," "should," "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "potential" or similar expressions. These
statements relate to future events or Vascudyne's clinical development programs,
reflect management's current beliefs and expectations and involve known and
unknown risks, uncertainties and other factors that may cause Vascudyne's actual
results, performance or achievements to be materially different. Vascudyne
undertakes no obligation to publicly update any forward-looking statements,
whether as a result of new information, future presentations or otherwise,
except as required by applicable law.

IMAGES

Vascudyne TRUE(TM) Graft First in Human Team

Vascudyne TRUE(TM) Graft

Vascudyne TRUE(TM) Graft Closeup

Contact Details

Sandy Williams

Marketing Director

mailto:[e-mail]

Company Website

https://www.vascudyne.com/

View source version on newsdirect.com: https://newsdirect.com/news/vascudyne-ann
ounces-successful-first-human-use-of-true-vascular-graft-for-hemodialysis-access
-352264410

2021 News Direct Corp.

Additional content: http://presseportal.de/pm/152041/4957722
OTS: News Direct